Drug Profile
Fevipiprant - Novartis
Alternative Names: NVP-QAW-039; QAW-039; QAW-39A; QAW39-A2107Latest Information Update: 22 Jul 2022
Price :
$50
*
At a glance
- Originator Novartis
- Class Acetic acids; Anti-inflammatories; Antiallergics; Antiasthmatics; Pyridines; Pyrroles; Skin disorder therapies
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic asthma; Allergic rhinitis; Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; Nasal polyps
Most Recent Events
- 22 Jul 2022 Discontinued - Phase-II for Allergic rhinitis in Germany (PO)
- 22 Jul 2022 Discontinued - Phase-II for Atopic dermatitis in Australia (PO)
- 22 Jul 2022 Discontinued - Phase-II for Atopic dermatitis in Austria (PO)